

Sté Aid'ARC 36, Comba dels Martirs 11570 PALAJA FRANCE



Carole DELAUNAY

SENIOR CLINICAL RESEARCH ASSOCIATE

Lead CRA Expert in Medical device

Age: 36 years Address:

Apt 14, 7 Bd Gambetta–76000 ROUEN– France (One hour from Paris)

Mob: +33 6.15.36.34.37

Area: France, Europe, all over the world.

PROFESSIONNAL EXPERIENCE

<u>Since February 2007</u>: CRA in the company Aid'ARC

<u>November 2006 to January 2007</u>: CRA in the CRC-INSERM-Rouen University Hospital.

EDUCATION

2017	IFIS "Training on the Law of 5 March 2012 known as Jardé, since the
	publication of Decree 2016-1537 of 16 November 2016 and the publication of the
	revision of Good Clinical Practice (ICH E6 (R2)."
2016	IFIS: Training "new European regulation for Clinical trial"
2013	SUNNIKAN CONSULTING: training "audit preparation at investigator site"
2011	SUNNIKAN CONSULTING: Training: "clinical research: French requirement"
	and "clinical research for devices in France"

2008	SUNNIKAN CONSULTING: Training of "New rules in clinical trials in France"
2006	D.U. Recherche et Développement clinique des Médicament: Diploma Approval on Clinical Research with ICH
2006	1 st year of MSc specialising in Ethology, Ecology and Evolution of Populations, passed with C grade.
2005	BSc degrees specialising in Biology of Organisms and Populations in University of Rennes1, passed with D grade.
2000	Baccalaureate of A levels specialising in Sciences with special emphasis in Biology.

LANGUAGE SKILLS

English: good working knowledge: (written and spoken), French (mother tongue), Spanish (basic knowledge).

SUMMARY OF EXPERIENCE

Experience in clinical trial monitoring (feasibility studies, investigators screening, initiation and monitoring and closeout visits, in coordination of a study.

Part of the project team as Lead CRA, involved in site management working in cooperation with local CRAs, Project Manager and other study divisions such as Safety, Data Management, Regulatory, legal, etc to ensure compliance to GCP/ICH/ISO and site performance. Review of study documents (Protocol, ICFs, Monitoring Plan, CRF, etc), creation of tools for CRAs.

Audit and inspections experience:

- as site monitor- on site audit: Sponsor audit preparation and support during audit for 2 sites: Medical devices with device accountability in Cardiology and Neurovascular.
 - as site monitor- review of the TMF and my dedicated site ISF by Japanese regulation and FDA for premarket study in Neuromodulation with device accountability.
 - As support/reviewer at site: Spain, Austria, France at site (sponsor audit, FDA inspection)
 - As support/reviewer -remotely as Lead CRA: Australian EC inspection, Israelian MoH inspection.

Therapeutics areas of experience: Cardiology (Arterial Hypertension, Myocardial Infarction, Endocarditis, Heart failure), Dermatology (Scleroderma), Endocrinology (Diabetes), Gastroenterology (Oesophageal reflux), Nephrology (Renal failure / dialysis), Neurology (Epilepsia/Aneurysm/Parkinson Disease/Dystonia), Oncology (Breast Cancer), Rheumatology (Rheumatoid arthritis / Rheumatoid spondylitis), Surgery (Knee surgery). Cardia Rhythm Management (Pacemaker), Cardiac Surgery (Valves)

CARDIOLOGY

Phase	Pathology	Detail of activities
IV	Arterial Hypertension	- Investigators screening

Observational Study	Myocardial Infarction	 Creation of the study documents (flow chart, study summary, PIC, CRF, forms, newsletters,) Management of the regulatory and adminitrativ file (CPP, AFSSAPS, CNO) Screening and training of Study-Nurses Management of the study logistics Initiation visits Monitoring Monitoring or Sites coordination (as Study-Nurse)
Investigation	Endocarditis	Sites coordination (as Study-Nurse)
III	Device (stent) Myocardial infarction	Initiation, Monitoring and Close-Out Visits
III	Device (stent) Myocardial infarction	Initiation, Monitoring and Close-Out Visits
III	Device (stent) Myocardial infarction	Monitoring Visits
III	Device (stent) Myocardial infarction	Initiation, Monitoring
III	Device (stent) Myocardial infarction	Initiation, Monitoring
IV	Heart failure and sleep troubles	Pre-study Visits
premarket	Device (algorythm for pacemaker)	Monitoring, closeout
postmarket	Device (cardiac valves)	Monitoring

DERMATOLOGY

Phase	Pathology	Detail of activities
I	Scleroderma	- Creation of a specific medical record for the patients included in the study, by the Phase I Center.
		- Work on the patients medical records

ENDOCRINOLOGY

Phase	Pathology	Detail of activities
III	Diabetes	- Investigators help in the patients screening
		 Creation of a specific medical record for the patients
		included in the study, by the Phase I Center.

GASTROENTEROLOGY

Phase	Pathology	Detail of activities
IV	Oesophageal reflux	Initiation, Monitoring and Close-Out Visits

NEPHROLOGY

Phase	Pathology	Detail of activities
Retrospectiv	Severe renal failure	Record in a e-CRF of the data of patients in dialysis

(Dialysis)	(Dialysis)	study
------------	------------	-------

NEUROLOGY

Phase	Pathology	Detail of activities
I without	Epilepsia	Creation of a specific medical record for the patients included
BID		in the study, by the Phase I Center.
IV	Aneurysm	Monitoring visit, closeout visits and activities. Submission to
	(Neurovascular)	Frenh EC and CA for protocol amendment, safety report and
	,	End of study in France and UK.
III	Parkinson Disease	French submission to EC/ CNOM, Site Qualification,
	(Neuromodulation)	management of site logistic. Initiation Visit, .Monitoring visit,
		closeout visit including device accountability, reconciliation
		at end of study.
IV	Failed Back Surgery	Monitoring visits, closeout visits, End of study submission,
	Syndrome	Study Monitoring visits, closeout visits, End of study
	(Neuromodulation)	submission, Study report submission.
		Site manager for OUS sites: ensure compliance with
		ICH/GCP, local regulation in Quebec, UK, Spain and France
		with 3 CRAs, review reports, coordination between CRAs
		and Project team (PM, safety, Data Management)
III	Back Pain	Site Management as Lead CRA: coordination of devices
	(Neuromodulation)	stock at study level, review of the shipment requested by site.
		: ensure compliance with ICH/GCP, local regulation in
		Australia, Spain and Belgium with 3 CRAs project support
		with UAT test for study e-crf, creation of study specific
TV /	D 1: D:	document, review of protocol.
IV	Parkinson Disease	Site Management as Lead CRA :Responsible for the
	(Neuromodulation)	performance of assigned sites in accordance with Good
		Clinical Practice (GCP), ICH guidelines and local regulations.
		Responsible for operational aspects of planning and
		management of site performance in Europe, Canada, Columbia with 12 CRAs. Project support with review and /or
		creation of study documents (ICF/protocol /monitoring
		plan/CRF). Budget creation. Contact with Marketing for
		nominated sites and new countries.
IV	Dystonia	Project support with review and creation of study documents
1 V	•	(ICF/protocol /monitoring plan, CRF). Contact with
	(Neuromodulation)	Marketing for nominated sites and new countries
		marketing for nonlinated sites and new countries

<u>ONCOLOGY</u>

Phase	Pathology	Detail of activities
Pharmaco	Breast Cancer	Initiation Visits
epidemio		
Investigation		
Observational	Breast Cancer	Site Coordination
study		

RHEUMATOLOGY

Phase Pathology	Detail of activities
-----------------	----------------------

Retrospectiv	Rheumatoid arthritis /	Data collection
study	Rheumatoid spondylitis	

SURGERY

Phase	Pathology	Detail of activities
III	Knee surgery	Monitoring.
(international)		

Date: 24 MAY 2017 Signature: